Breaking News, Financial News

Financial Report: Hospira 1Q

Specialty Injectable Pharmaceuticals up 13%

Hospira
 
1Q Revenues: $1.2 billion (+12%)

1Q Earnings: $75.6 million (+11%)

Comments: Growth in the quarter was driven by sales of Specialty Injectable Pharmaceuticals (SIP) in the U.S. (+17% to $665.5 million), as well as biosimilar sales in the Europe, Middle East and Africa (EMEA) segment. Global SIP sales were $808.5 million, up 13%. Sales growth offset the decline Precedex, which lost market exclusivity in 2H14.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters